PubMed:10608819 / 1355-1659 JSONTXT

{"project":"GlyCosmos6-Glycan-Motif-Image","denotations":[{"id":"T15","span":{"begin":17,"end":26},"obj":"Glycan_Motif"},{"id":"T16","span":{"begin":259,"end":268},"obj":"Glycan_Motif"}],"attributes":[{"id":"A15","pred":"image","subj":"T15","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G02149VR"},{"id":"A16","pred":"image","subj":"T16","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G02149VR"}],"text":"Notably, a novel GT1aalpha analog with sulfates at two internal sites of sialylation (NeuAcalpha2,3Galbeta1,4GalNAc-6-sulfatebeta1, 4Gal3-sulfatebeta1,4Glcbeta1,1'ceramide) was the most potent siglec-binding structure tested to date (10-fold more potent than GT1aalpha in supporting MAG and SMP binding)."}

{"project":"sentences","denotations":[{"id":"T6","span":{"begin":0,"end":304},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Notably, a novel GT1aalpha analog with sulfates at two internal sites of sialylation (NeuAcalpha2,3Galbeta1,4GalNAc-6-sulfatebeta1, 4Gal3-sulfatebeta1,4Glcbeta1,1'ceramide) was the most potent siglec-binding structure tested to date (10-fold more potent than GT1aalpha in supporting MAG and SMP binding)."}

{"project":"GlyCosmos6-Glycan-Motif-Structure","denotations":[{"id":"T15","span":{"begin":17,"end":26},"obj":"https://glytoucan.org/Structures/Glycans/G02149VR"},{"id":"T16","span":{"begin":259,"end":268},"obj":"https://glytoucan.org/Structures/Glycans/G02149VR"}],"text":"Notably, a novel GT1aalpha analog with sulfates at two internal sites of sialylation (NeuAcalpha2,3Galbeta1,4GalNAc-6-sulfatebeta1, 4Gal3-sulfatebeta1,4Glcbeta1,1'ceramide) was the most potent siglec-binding structure tested to date (10-fold more potent than GT1aalpha in supporting MAG and SMP binding)."}

{"project":"Glycosmos6-GlycoEpitope","denotations":[{"id":"T8","span":{"begin":17,"end":26},"obj":"http://www.glycoepitope.jp/epitopes/EP0111"},{"id":"T9","span":{"begin":259,"end":268},"obj":"http://www.glycoepitope.jp/epitopes/EP0111"}],"text":"Notably, a novel GT1aalpha analog with sulfates at two internal sites of sialylation (NeuAcalpha2,3Galbeta1,4GalNAc-6-sulfatebeta1, 4Gal3-sulfatebeta1,4Glcbeta1,1'ceramide) was the most potent siglec-binding structure tested to date (10-fold more potent than GT1aalpha in supporting MAG and SMP binding)."}

{"project":"Glycan-GlyCosmos","denotations":[{"id":"T23","span":{"begin":17,"end":26},"obj":"Glycan"},{"id":"T24","span":{"begin":259,"end":268},"obj":"Glycan"}],"attributes":[{"id":"A23","pred":"glycosmos_id","subj":"T23","obj":"https://glycosmos.org/glycans/show/G02149VR"},{"id":"A48","pred":"image","subj":"T23","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G02149VR"},{"id":"A24","pred":"glycosmos_id","subj":"T24","obj":"https://glycosmos.org/glycans/show/G02149VR"},{"id":"A49","pred":"image","subj":"T24","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G02149VR"}],"text":"Notably, a novel GT1aalpha analog with sulfates at two internal sites of sialylation (NeuAcalpha2,3Galbeta1,4GalNAc-6-sulfatebeta1, 4Gal3-sulfatebeta1,4Glcbeta1,1'ceramide) was the most potent siglec-binding structure tested to date (10-fold more potent than GT1aalpha in supporting MAG and SMP binding)."}

{"project":"GlyCosmos-GlycoEpitope","denotations":[{"id":"T8","span":{"begin":17,"end":26},"obj":"http://purl.jp/bio/12/glyco/glycan#Glycan_epitope"},{"id":"T9","span":{"begin":259,"end":268},"obj":"http://purl.jp/bio/12/glyco/glycan#Glycan_epitope"}],"attributes":[{"id":"A8","pred":"glycoepitope_id","subj":"T8","obj":"http://www.glycoepitope.jp/epitopes/EP0111"},{"id":"A9","pred":"glycoepitope_id","subj":"T9","obj":"http://www.glycoepitope.jp/epitopes/EP0111"}],"text":"Notably, a novel GT1aalpha analog with sulfates at two internal sites of sialylation (NeuAcalpha2,3Galbeta1,4GalNAc-6-sulfatebeta1, 4Gal3-sulfatebeta1,4Glcbeta1,1'ceramide) was the most potent siglec-binding structure tested to date (10-fold more potent than GT1aalpha in supporting MAG and SMP binding)."}

{"project":"sentences","denotations":[{"id":"T6","span":{"begin":0,"end":304},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Notably, a novel GT1aalpha analog with sulfates at two internal sites of sialylation (NeuAcalpha2,3Galbeta1,4GalNAc-6-sulfatebeta1, 4Gal3-sulfatebeta1,4Glcbeta1,1'ceramide) was the most potent siglec-binding structure tested to date (10-fold more potent than GT1aalpha in supporting MAG and SMP binding)."}

{"project":"GlyCosmos15-Sentences","blocks":[{"id":"T6","span":{"begin":0,"end":304},"obj":"Sentence"}],"text":"Notably, a novel GT1aalpha analog with sulfates at two internal sites of sialylation (NeuAcalpha2,3Galbeta1,4GalNAc-6-sulfatebeta1, 4Gal3-sulfatebeta1,4Glcbeta1,1'ceramide) was the most potent siglec-binding structure tested to date (10-fold more potent than GT1aalpha in supporting MAG and SMP binding)."}

{"project":"GlyCosmos15-Glycan","denotations":[{"id":"T23","span":{"begin":17,"end":26},"obj":"Glycan"},{"id":"T24","span":{"begin":259,"end":268},"obj":"Glycan"}],"attributes":[{"id":"A23","pred":"glycosmos_id","subj":"T23","obj":"https://glycosmos.org/glycans/show/G02149VR"},{"id":"A48","pred":"image","subj":"T23","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G02149VR"},{"id":"A24","pred":"glycosmos_id","subj":"T24","obj":"https://glycosmos.org/glycans/show/G02149VR"},{"id":"A49","pred":"image","subj":"T24","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G02149VR"}],"text":"Notably, a novel GT1aalpha analog with sulfates at two internal sites of sialylation (NeuAcalpha2,3Galbeta1,4GalNAc-6-sulfatebeta1, 4Gal3-sulfatebeta1,4Glcbeta1,1'ceramide) was the most potent siglec-binding structure tested to date (10-fold more potent than GT1aalpha in supporting MAG and SMP binding)."}

{"project":"GlyCosmos15-GlycoEpitope","denotations":[{"id":"T8","span":{"begin":17,"end":26},"obj":"http://purl.jp/bio/12/glyco/glycan#Glycan_epitope"},{"id":"T9","span":{"begin":259,"end":268},"obj":"http://purl.jp/bio/12/glyco/glycan#Glycan_epitope"}],"attributes":[{"id":"A8","pred":"glycoepitope_id","subj":"T8","obj":"http://www.glycoepitope.jp/epitopes/EP0111"},{"id":"A9","pred":"glycoepitope_id","subj":"T9","obj":"http://www.glycoepitope.jp/epitopes/EP0111"}],"text":"Notably, a novel GT1aalpha analog with sulfates at two internal sites of sialylation (NeuAcalpha2,3Galbeta1,4GalNAc-6-sulfatebeta1, 4Gal3-sulfatebeta1,4Glcbeta1,1'ceramide) was the most potent siglec-binding structure tested to date (10-fold more potent than GT1aalpha in supporting MAG and SMP binding)."}